volume 10, issue 1, P509-519 2021
DOI: 10.21037/tcr-20-3329
View full text

Abstract: Background: Breast cancer recurrence and mortality have been shown to decrease after trastuzumab treatment in human epidermal growth factor 2 (HER2)-positive early-stage breast cancer (EBC) patients. In Jiangsu Province, trastuzumab has been subsidized for patients with HER2-positive EBC since 2013. Several studies showed that Jiangsu was one of the provinces with the highest rates of adjuvant trastuzumab therapy.To uncover the underlying reason, we designed the study to investigate trastuzumab use for HER2-po…

expand abstract